However, due to the limited effects of enzyme inhibitor complex and LRP1 pro-survival signal triggering in the early stage of STEMI, it is not sufficient to combat the excessive inflammatory response in the early infarction area, so serine protease inhibitors (plasma-derived AAT, SP16, etc.), which act as LRP1 agonists, are more commonly developed and used in STEMI ischemia-reperfusion. Here, SERPINA1 is linked to infarction.